Bristol-Myers earnings could double by end of decade, says Goldman

March 22, 2013

Goldman believes Bristol-Myers earnings could double ty the end of the decade given by PD-1 contribution. The firm believes investors are underestimating PD-1 and that peak sales could reach $7B by 2025. The firm reiterates its Conviction Buy rating and raised its price target to $44 from $40.